Aardvark Therapeutics’ (AARD) Outperform Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a $21.00 price objective on the stock.

Other research analysts also recently issued research reports about the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $50.00 price target on shares of Aardvark Therapeutics in a report on Tuesday. Morgan Stanley started coverage on Aardvark Therapeutics in a research note on Monday, March 10th. They set an “overweight” rating and a $29.00 target price for the company. Finally, Bank of America raised their price target on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Thursday, March 27th.

Aardvark Therapeutics Price Performance

Shares of AARD stock opened at $8.29 on Tuesday. Aardvark Therapeutics has a 12 month low of $6.79 and a 12 month high of $19.58.

Insiders Place Their Bets

In other Aardvark Therapeutics news, CFO Nelson Sun bought 10,000 shares of the company’s stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $16.00 per share, with a total value of $160,000.00. Following the completion of the acquisition, the chief financial officer now owns 99,484 shares of the company’s stock, valued at approximately $1,591,744. This trade represents a 11.18 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Tien-Li Lee purchased 16,542 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was acquired at an average cost of $16.00 per share, with a total value of $264,672.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,496,175 shares in the company, valued at approximately $23,938,800. This trade represents a 1.12 % increase in their position. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.